-
公开(公告)号：US20100015644A1
公开(公告)日：2010-01-21
申请号：US11989064
申请日：2006-07-21
IPC分类号： G01N33/53 , G01N33/566 , C07K16/18 , C12M1/22
CPC分类号： C07K16/2812 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/732 , C07K2317/76 , G01N33/566 , G01N2333/70535
摘要： The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.
摘要翻译： 本发明涉及一种表征抗体的方法，该方法适用于批量释放包含抗体的药物组合物的效力测定，该抗体特别用于在申请所述药物组合物的营销授权时使用。 提供的测定法是用于测定包含FcR结合肽的药物产品的效力的方法，其中药物产物的FcR结合肽的至少一种作用机制是通过药物产物的FcR结合肽的结合来介导的 其中所述方法包括测定药物产物的FcR结合肽与Fc受体的结合。
-
公开(公告)号：US09580506B2
公开(公告)日：2017-02-28
申请号：US11989064
申请日：2006-07-21
IPC分类号： G01N33/53 , C07K16/28 , G01N33/566 , C07K16/00
CPC分类号： C07K16/2812 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/732 , C07K2317/76 , G01N33/566 , G01N2333/70535
摘要： The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.
摘要翻译： 本发明涉及一种表征抗体的方法，该方法适用于批量释放包含抗体的药物组合物的效力测定，该抗体特别用于在申请所述药物组合物的营销授权时使用。 提供的测定法是用于测定包含FcR结合肽的药物产品的效力的方法，其中药物产物的FcR结合肽的至少一种作用机制是通过药物产物的FcR结合肽的结合来介导的 其中所述方法包括测定药物产物的FcR结合肽与Fc受体的结合。
-
公开(公告)号：US08182812B2
公开(公告)日：2012-05-22
申请号：US12283775
申请日：2008-09-16
申请人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jorgen Petersen , Ole Baadsgaard
发明人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jorgen Petersen , Ole Baadsgaard
IPC分类号： A61K39/395 , A61P37/02 , A61P37/08 , G01N33/53
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
摘要： Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
摘要翻译： 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。
-
公开(公告)号：US07438907B2
公开(公告)日：2008-10-21
申请号：US10714353
申请日：2003-11-14
申请人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jørgen Petersen , Ole Baadsgaard
发明人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jørgen Petersen , Ole Baadsgaard
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
摘要： Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
摘要翻译： 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。
-
公开(公告)号：US08961968B2
公开(公告)日：2015-02-24
申请号：US13465181
申请日：2012-05-07
申请人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jørgen Petersen , Ole Baadsgaard
发明人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jørgen Petersen , Ole Baadsgaard
IPC分类号： C07K16/28 , C07K17/00 , G01N33/577 , A61K51/10 , A61K39/395 , G01N33/68 , A61K39/00
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
摘要： Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
-
公开(公告)号：US20090081219A1
公开(公告)日：2009-03-26
申请号：US12283775
申请日：2008-09-16
申请人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G.J. Van De Winkel , Denise Leah Williams , Jorgen Petersen , Ole Baadsgaard
发明人： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G.J. Van De Winkel , Denise Leah Williams , Jorgen Petersen , Ole Baadsgaard
IPC分类号： A61K39/395 , G01N33/53 , A61P37/02 , A61P37/08
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
摘要： Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
摘要翻译： 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。
-
公开(公告)号：US20100267934A1
公开(公告)日：2010-10-21
申请号：US12602439
申请日：2008-05-30
申请人： Jan Van De Winkel , Tom Vink , Janine Schuurman , Paul Parren , Rob Aalberse , Marijn Van Der Neut Kolfschote
发明人： Jan Van De Winkel , Tom Vink , Janine Schuurman , Paul Parren , Rob Aalberse , Marijn Van Der Neut Kolfschote
CPC分类号： C07K16/2887 , A61K47/6803 , A61K47/6813 , A61K47/6835 , A61K47/6839 , A61K47/6845 , A61K47/6849 , A61K51/10 , A61K51/1006 , A61K51/1021 , A61K51/1027 , A61K51/103 , A61K51/1039 , A61K2039/505 , C07K16/00 , C07K16/16 , C07K16/18 , C07K16/28 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/94
摘要： The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
摘要翻译： 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。
-
8.发明申请METHOD FOR EXTENDING THE HALF-LIFE OF EXOGENOUS OR ENDOGENOUS SOLUBLE MOLECULES 审中-公开扩增异源或内源可溶性分子半衰期的方法公开(公告)号：US20100291023A1
公开(公告)日：2010-11-18
申请号：US12602434
申请日：2008-05-30
申请人： Janine Schuurman , Tom Vink , Jan Van de Winkel , Aran Frank Labrijn , Paul Parren , Frank Beurskens , Willem Karel Bleeker , Patrick Van Berkel
发明人： Janine Schuurman , Tom Vink , Jan Van de Winkel , Aran Frank Labrijn , Paul Parren , Frank Beurskens , Willem Karel Bleeker , Patrick Van Berkel
IPC分类号： A61K38/20 , A61K38/21 , A61K39/395 , C07K16/44 , C07K16/42
CPC分类号： C07K16/283 , C07K16/2812 , C07K16/2863 , C07K16/2887 , C07K2317/732
摘要： The present invention relates to methods for extending the in vivo half-life of an exogenous soluble therapeutic molecule administered to a subject, by administering to said subject the exogenous soluble molecule and a monovalent antibody that binds to the exogenous soluble molecule, as well as method for treating a disease or disorder associated with an insufficient level of an endogenous soluble molecule in a subject, by administering to said subject a monovalent antibody that binds to the endogenous soluble molecule.
摘要翻译： 本发明涉及通过向所述受试者施用外源可溶性分子和结合外源可溶性分子的单价抗体以及方法，用于延长给予受试者的外源可溶性治疗分子的体内半衰期的方法，以及方法 用于治疗与受试者内源性可溶性分子水平不足相关的疾病或病症，通过向所述受试者施用结合内源性可溶性分子的单价抗体。
-
公开(公告)号：US20100105874A1
公开(公告)日：2010-04-29
申请号：US12593759
申请日：2008-03-28
申请人： Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Rob Aalberse , Marijn Van Der Neut Kolfschote , Paul Parren
发明人： Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Rob Aalberse , Marijn Van Der Neut Kolfschote , Paul Parren
CPC分类号： C07K16/468 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2319/00
摘要： The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
摘要翻译： 本发明涉及用于产生双特异性抗体的离体方法，包括以下步骤：a）提供具有第一结合特异性的第一抗体，其中所述第一抗体包含IgG4样CH3区，b）提供第二抗体 具有不同于所述第一结合特异性的第二结合特异性的抗体，其中所述第二抗体包含IgG4样CH3区，c）在还原条件下将所述第一抗体和第二抗体一起温育，所述还原条件允许核心铰链区域中的半胱氨酸经历二硫键 异构化，和d）获得双特异性抗体。 本发明还涉及通过本发明的方法可获得的双特异性抗体。
-
公开(公告)号：US09212230B2
公开(公告)日：2015-12-15
申请号：US12593759
申请日：2008-03-28
申请人： Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Rob Aalberse , Marijn Van Der Neut Kolfschote , Paul Parren
发明人： Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Rob Aalberse , Marijn Van Der Neut Kolfschote , Paul Parren
CPC分类号： C07K16/468 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2319/00
摘要： The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
摘要翻译： 本发明涉及用于产生双特异性抗体的离体方法，包括以下步骤：a）提供具有第一结合特异性的第一抗体，其中所述第一抗体包含IgG4样CH3区，b）提供第二抗体 具有不同于所述第一结合特异性的第二结合特异性的抗体，其中所述第二抗体包含IgG4样CH3区，c）在还原条件下将所述第一抗体和第二抗体一起温育，所述还原条件允许核心铰链区域中的半胱氨酸经历二硫键 异构化，和d）获得双特异性抗体。 本发明还涉及通过本发明的方法可获得的双特异性抗体。
-
-
-
-
-
-
-
-
-
搜索结果
91 条记录 (耗时 0.034 秒)
